Secondary End Points
hemorrhage, death
ADVERSE EVENTS, HEMORRHAGE
Secondary end points were treatment-associated grade 4 hemorrhage or treatment-associated grade 5 adverse events after the first year, death during treatment or within 30 days of treatment completion (regardless of the cause of death), other grade 3 to 5 adverse events, feeding tube use rates, treatment tolerability (for each treatment component, concurrent and adjuvant), locoregional progression–free (LRPF) interval, DMF interval, PFS, and OS. Long-term treatment–associated AEs and clinical outcomes (OS, PFS, LRPF interval, and DMF interval), including 5- and 7-year rates, that were not specified in the protocol are reported for this study.